Vistagen Therapeutics Inc(VTGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.7 | Insider Own | 0.42% | Shs Outstand | 44.4M | Perf Week | -6.34% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -4.41% | Insider Trans | - | Shs Float | 44.2M | Perf Month | -40.45% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | -0.38 | Inst Own | 26.94% | Short Float | 5.6% | Perf Quarter | -31.31% |
| Income | -0.07B | P/S | 2.99 | EPS this Y | 19.4% | Inst Trans | -11.76% | Short Ratio | 0.2 | Perf Half Y | -73.11% |
| Sales | 0.00B | P/B | 0.31 | EPS next 5Y | 3.2% | ROA | -129.22% | Short Interest | 2.47M | Perf YTD | -74.57% |
| Book/sh | 0.55 | P/C | 0.24 | EPS past 3/5Y | 40.1% 34.11% | ROE | -166.46% | 52W High | -96.73% ($5.14) | Perf Year | -95.51% |
| Cash/sh | 0.71 | P/FCF | - | Sales past 3/5Y | - 3.1% | ROIC | -275.51% | 52W Low | 1.75% ($0.17) | Perf 3Y | -94.55% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -7.55% | Gross Margin | 69.58% | Volatility(W/M) | 5.24% 6.75% | Perf 5Y | -99.76% |
| Dividend TTM | - | EV/Sales | -9.39 | Sales Y/Y TTM | - | Oper. Margin | -2784.33% | ATR (14) | 0.02 | Perf 10Y | -99.86% |
| Dividend Ex-Date | - | Quick Ratio | 3.07 | EPS Q/Q | 35.86% | Profit Margin | -2702.64% | RSI (14) | 29.48 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.07 | Sales Q/Q | 504.92% | SMA20 | -18.34% ($0.21) | Beta | 0.42 | Target Price | $1 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/14 | SMA50 | -29.21% ($0.24) | Rel Volume | 0.05 | Prev Close | $0.17 |
| Employees | 41 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 17.81% 195.2% | SMA200 | -62.2% ($0.45) | Avg Volume(3M) | 12.15M | Price | $0.17 |
| IPO | 2011/6/21 | Option/Short | Yes/Yes | Trades | 608 | Volume | 594,790 | Change | -1.41% |
🧠 This is a US late-stage clinical biopharmaceutical company developing a nasal spray drug candidate from the 'Pherine' family, which regulates anxiety and emotions through the olfactory neural circuit connecting the nasal mucosa to the brain. The company's lead candidate, Fasedienol (PH94B), is being developed as an acute treatment for social anxiety disorder (SAD).
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual. That is 5% of its average volume.
VTGN has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +19.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $299. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 26.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #521 of 597 in the industry
Based on market cap of $7M.
SNGX#520 Soligenix Inc $8M PER - VTGN#521 Vistagen Therapeutics Inc $7M PER - 
MTVA#522 MetaVia Inc $7M PER - 
LEXX#523 Lexaria Bioscience Corp $7M PER - 
CNSP#524 Cns Pharmaceuticals Inc $7M PER - 
FAQ
What kind of company is VTGN?
VTGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VTGN?
The market cap of VTGN is approximately $7M, ranking 5,515 within its sector.
What is the 52-week high and low for VTGN?
VTGN has recorded a 52-week high of $5.14 and a low of $0.17.
